FDA seeks permanent injunctions against two stem cell clinics

	Actions part of a comprehensive approach to the oversight of regenerative medicine products
	The U.S. Food and Drug Administration, in two complaints filed today in federal court, is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements. Continue reading.